Biotech News

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

Exelixis (EXEL)Exelixis2026-06-25 13:46 ESTClinical readout

– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo – ALAMEDA, Calif. --(BUSINESS WIRE)--May 30, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced results from a

Open original release

Related news

EXELExelixis2026-06-25 13:46 EST

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

EXELExelixis2026-06-25 13:46 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

EXELExelixis2026-06-25 13:46 EST

Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types

EXELExelixis2026-06-25 13:46 EST

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

EXELExelixis2026-06-25 13:46 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May

EXELExelixis2026-06-25 13:46 EST

Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025

EXELExelixis2026-06-25 13:46 EST

Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026

EXELExelixis2026-06-25 13:46 EST

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

EXELExelixis2026-06-25 13:46 EST

Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

EXELExelixis2026-06-25 13:46 EST

Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026

View all latest news

Exelixis

Exelixis is an oncology-focused biopharmaceutical company best known for its established commercial base and continued pipeline work in cancer. Investors follow the stock for launch durability and the next wave of oncology catalysts.

Recent company news

EXELExelixis2026-06-26 07:29 EST

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

EXELExelixis2026-06-26 07:29 EST

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

EXELExelixis2026-06-26 07:29 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

EXELExelixis2026-06-26 07:29 EST

Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types

EXELExelixis2026-06-26 07:29 EST

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States